Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010 Nov;9(11):1118-27. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Aduhelm

News

  1. DC: Biomarkers, Parkinson’s—CAMD Needs All Hands on Deck
  2. Detecting Familial AD Ever Earlier: Subtle Memory Signs 15 Years Before
  3. Revised Diagnostic Criteria for Alzheimer’s Are Published
  4. London: What, No Argument? Speakers Agree on Trials for Familial AD
  5. Researchers Join to Draw Posterior Cortical Atrophy Out of Shadows
  6. The EMA Deems Brain Atrophy Valid Trial Selection Measure
  7. Will Technology Revolutionize Dementia Diagnosis and Care?
  8. Miami: Is Human Amyloid Imaging Ready for Clinical Trials?
  9. Clinical Trials: Task Force Supports Earlier Intervention
  10. Paris: Beyond Genomics, French Science Draws on Populations, Patients
  11. Is Structural MRI Closing In on Preclinical AD Biomarker?
  12. Safe at 4 Grams? No ARIA at High Dose of Human Aβ Antibody
  13. Are New Cognitive Tests Ready For Preclinical Trials?

Webinars

  1. Two New Sets of Diagnostic Criteria—Which Is Right for Your Clinic?

Research Timeline Event

  1. International Working Group revises AD diagnosis, uses biomarkers to capture early stage